APA (7th ed.) Citation

GK, P., JB, P., O, A., AE, F., D, C., W, T., . . . M, K. (2020). Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review. Journal of cancer research and therapeutics, 16(4), 950. https://doi.org/10.4103/jcrt.JCRT_729_18

Chicago Style (17th ed.) Citation

GK, Patel, et al. "Epidermal Growth Factor Receptor-activating Mutation(E746_T751>VP) in Pancreatic Ductal Adenocarcinoma Responds to Erlotinib, Followed by Epidermal Growth Factor Receptor Resistance-mediating Mutation (A647T): A Case Report and Literature Review." Journal of Cancer Research and Therapeutics 16, no. 4 (2020): 950. https://doi.org/10.4103/jcrt.JCRT_729_18.

MLA (9th ed.) Citation

GK, Patel, et al. "Epidermal Growth Factor Receptor-activating Mutation(E746_T751>VP) in Pancreatic Ductal Adenocarcinoma Responds to Erlotinib, Followed by Epidermal Growth Factor Receptor Resistance-mediating Mutation (A647T): A Case Report and Literature Review." Journal of Cancer Research and Therapeutics, vol. 16, no. 4, 2020, p. 950, https://doi.org/10.4103/jcrt.JCRT_729_18.